Press & Statements

CSRxP STATEMENT ON PRESIDENT TRUMP’S MOST FAVORED NATION EXECUTIVE ORDER

May 13, 2025

Administration Rightly Diagnoses Big Pharma’s Egregious Pricing Practices as Read More

CSRxP LAUNCHES SIX-FIGURE ADVERTISING CAMPAIGN TO HOLD BIG PHARMA ACCOUNTABLE FOR ANTICOMPETITIVE PRACTICES AND EGREGIOUS DRUG PRICING

Apr 28, 2025

Campaign Spoofs Big Pharma’s Direct-to-Consumer (DTC) Ads While Highlighting Read More

CSRxP STATEMENT ON U.S. SENATE AND U.S. HOUSE REINTRODUCTION OF Q1/Q2 REFORMS TO FOSTER GREATER COMPETITION, LOWER DRUG PRICES

Apr 15, 2025

Lawmakers Should Advance Bipartisan Solution to Crack Down on Anti-Competitive Read More

FACT SHEET: BIG PHARMA’S PATENT ABUSE COSTS AMERICAN PATIENTS, TAXPAYERS AND THE U.S. HEALTH CARE SYSTEM BILLIONS OF DOLLARS

Apr 2, 2025

BIG PHARMA’S PATENT ABUSE IS THE ROOT CAUSE OF OUT-OF-CONTROL PRESCRIPTION Read More

CSRxP ANALYSIS FINDS BIG PHARMA’S DIRECT-TO-CONSUMER (DTC) ADVERTISING COSTS U.S. TAXPAYERS BILLIONS OF DOLLARS

Mar 18, 2025

Study Finds Reducing or Taxing Brand Name Drug Companies’ Nearly $14 Billion Read More

CSRxP STATEMENT ON CONFIRMATION OF RFK JR AS SECRETARY OF U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES

Feb 13, 2025

Campaign Looks Forward to Working with Kennedy and the Administration to Lower Read More

CSRxP: BIG PHARMA BACK AT IT WITH EGREGIOUS PRICE HIKES OUTPACING INFLATION TO RING IN 2025

Jan 2, 2025

Brand Name Drug Companies Signal Business-as-Usual Approach to Price-Gouging Read More